Our Resident Network
Meet Our Residents
LabCentral has generated significant interest from entrepreneurs and startups working on groundbreaking science who are eager to join LabCentral, a first-of-its-kind, fully resourced and equipped life-sciences laboratory space. Participants are chosen through a competitive process, where only the highest-potential applicants are selected in keeping with our mission.
AcousticaBio is an advanced manufacturing company solving the greatest challenges in drug delivery for novel therapeutics. Today, millions of patients face the burden of frequent hospital visits, enduring painful, costly, and time-consuming intravenous (IV) injections to receive their life-saving medications. AcousticaBio transforms this process, making drug delivery as simple as receiving a routine flu shot. Utilizing advanced microparticle technology and our Harvard-patented acoustophoretic platform, we convert intravenously delivered biologic products into highly concentrated, small-volume subcutaneous injections – all without the use of solvents or cumbersome post-processing.
AIRNA brings together leading academic scientists that pioneered a new field of precisely targeting RNA. The company's medicines will be antisense oligonucleotides which are specifically delivered to target tissues and make precise modifications to alter the RNA or associated protein function, interaction, or form. The company has licensed a strong patent portfolio to be a leader in this emerging field.
Research Area:
Drug Discovery / Development
Oligonucleotide Drug
Atias Pharma is a biopharmaceutical company focused on developing novel therapeutic drugs in areas of high unmet medical need, combining insights into the physiology and pathophysiology of targets with a deep molecular understanding of target ligand-receptor interactions to enable novel drug discovery.
BioDevek leverages materials science, biology, and medicine to develop the next generation of biomaterial-based surgical solutions to improve the clinical outcomes following internal surgeries.
Research Area:
Platform Technology
Drug Delivery
Cerberus Therapeutics is pioneering an alpaca-derived single domain antibody fragment (VHH)-based platform to create novel therapeutics capable of immune modulation. Their initial programs focus on developing therapies for several autoimmune disorders, as well as tolerance against immune reactions to Adeno-Associated Virus ("AAV") vectors. By incorporating genetic and biochemical protein modification strategies, Cerebus has shown that just a single dose of these engineered VHHs achieve robust in vivo efficacy in preclinical mouse models of several autoimmune diseases including multiple sclerosis, type I diabetes, and rheumatoid arthritis, both prophylactically and therapeutically.
DaCapo Brainscience, Inc. is built to create revolutionary, disease-modifying therapeutics for neurological diseases. DaCapo is fusing a unique understanding of biological systems, their induced pluripotent stem cell (iPSC)-based neuronal culture systems, their proprietary analyses of patient databases, and their pioneering AI/ML algorithms to create an integrated platform for disease-definition and target discovery. With this platform, DaCapo Brainscience can identify novel molecular subtypes of disease and corresponding drug targets for synucleinopathies (such as Parkinson's Disease and Lewy Body Dementia) and other neurodegenerative diseases.
Epitope has identified specific sequence (epitopes) that lead to the generation of pathogenic antibodies, the underlying driver of a number of auto-immune disorders. Epitope's lead program uses a proprietary peptide display technology that will target and neutralise / eliminate the pathogenic antibodies, supporting patients who suffer Bullous Pemphigoid, a skin condition that one of the companies founders has been researching and treating over several decades.
Research Area:
Drug Discovery / Development
Small Molecules
Our aim is to develop a novel domain for immune recruitment for bispecific T cell engagers that specifically recruits immune cells in an activated, cytotoxic state. To do this, we are designing therapeutics that mimic antigens from common infectious diseases. In effect, our therapeutics will direct potent, existing immune responses for an infectious disease (e.g. SARS-CoV-2, influenza) towards a cancer, leading to a more precise and efficacious response.
Research Area:
Drug Discovery / Development
Recombinant Therapeutic Protein
GC Therapeutics (GCTx) is the first cell therapy company with an integrated synthetic biology and AI-driven cell differentiation platform powered by the only genome-wide cell landscape exploration approach for streamlined biomanufacturing. GCTx's technology allows for the development of any cell therapy from stem cells with an accelerated timeline of 4 days (compared to months) with up to 100% differentiation efficiency (compared to 10%) in a highly scalable process.
GelMEDIX is a platform-based company focused on developing bioadhesive hydrogel drug depots to improve patient compliance and treatment outcomes in ophthalmology. GelMEDIX was founded based upon 8 years of academic work originating at Massachusetts Eye and Ear, Harvard Medical School, Northeastern University, and UCLA that was motivated by challenges in post-op and chronic treatment in ophthalmology.
Research Area:
Biological Product
Cell Therapy
Coming Soon
Research Area:
Drug Discovery / Development
Recombinant Therapeutic Protein
Gensaic is a phage-derived particle (PDP) gene delivery platform that addresses key limitations in the current gene therapy landscape. Unlike the market lead AAV technology, PDPs offer durable therapeutic efficacy via repeat administration, enable tissue-specific targeting, support massively scalable manufacturing, and can package any full-length human gene as a therapeutic (>20 kb).
Research Area:
Biological Product
Gene Therapy
Harton is an early-stage biotechnology company formed with the vision of transforming healthcare, therapeutics, and diagnostics, through our iterative design, build, test platform. Our platform designs modular engineered proteins and cells via AI, builds at unlimited scale using synthetic gene libraries, and continually tests on patient samples utilizing all forms of sequencing from next-gen sequencing, to single-cell, to spatial. Harton's mission is to transform healthcare by delivering next-generation precision-engineered therapeutics linking cellular and targeting discovery technologies to advanced therapeutic designs. In the future, libraries of characterized modular therapeutic components will enable rapid development of safe & effective personalized drugs.
Research Area:
Biological Product
Cell Therapy
Biologics command a large share of the therapeutics market but are limited to injection-based therapies due to poor oral bioavailability. This administration route results in increased healthcare costs and poor patient compliance. i2O Therapeutic's ionic liquid platform enables the oral delivery of such drugs, alleviating the patient burden for these therapies.
Research Area:
Platform Technology
Drug Delivery
Ilios Tx is a small molecules drug discovery platform that creates first-in-class disease-modifying drugs to treat neurodegenerative diseases.
Research Area:
Drug Discovery / Development
Small Molecules
InGel Tx technology is an injectable biomimetic hydrogel platform engineered for the sustained release of stem cells and drugs in the eye, initially targeting regenerative medicine for retinitis pigmentosa, macular degeneration and geographic atrophy.
Research Area:
Biological Product
Cell Therapy
InnDura develops Armed Cytokine-Induced Memory-Like NK cells (CIML NK cells). In clinical trials CIML NK cells have been shown to have significantly enhanced properties of potency, proliferation and persistence when compared to conventional NK cells, whilst retaining their excellent safety profile when compared to CAR-T therapies. Using InnDura's proprietary NAS-CAR manufacturing, InnDura can genetically engineer these CIML NK Cells to further enhance their efficacy against a range of hematologic and solid tumors. InnDura's platform technology thus delivers benefits over both CAR-T therapeutics and conventional NK cell therapeutics.
Research Area:
Biological Product
Cell Therapy
Coming Soon
Research Area:
Drug Discovery / Development
Small Molecules
Genetic medicines are now beginning to make a major impact on human disease, with transformative RNAi, ASO, mRNA, and gene therapies now approved drugs. Delivery of these medicines to target tissues remains the major roadblock to extending these modalities to additional diseases. Conjugation strategies targeting specific receptors such as GalNAC-ASGRP and transferrin receptor binding mAbs and peptides have been opened new tissues such as the liver and skeletal muscle to these medicines. Judo Bio will extend this strategy to targeting specific cell populations in the kidney for the treatment of renal and systemic metabolic diseases.
Research Area:
Drug Discovery / Development
Small Molecules
K2B is a pre-clinical stage therapeutics discovery startup, with the goal of commercializing a game-changing protein-RNA conjugate in the immune-oncology space.
Research Area:
Biological Product
Gene Therapy
Kano Therapeutics believes that innovative drugs need innovative supply chains. Kano is building a bio-infrastructure company to solve the huge bioprocessing capacity crunch in therapeutic manufacturing for cell and gene therapy companies. Kano's immediate focus lies on a new type of genetic vector for CRISPR applications that enables their customers to get their innovative drugs faster in and through clinical trials.
Research Area:
Biological Product
Gene Therapy
Kern System's mission is to provide the first permanent data archive infrastructure for the rapidly expanding digital universe. Kern Systems will offer customers a cost-effective way to archive data without material risk of loss, overheads associated with data maintenance, and obsolescence.
Research Area:
Platform Technology
R&D Tool
Kernal Bio is a biotech company developing mRNA 2.0 immunotherapies. Kernal mines translatome data to discover cell-specific sequence features and design mRNAs that are selectively translated in cancer cells. These mRNAs are formulated with proprietary, best-in-class LNPs validated in non-human primates. Our development candidates have a remarkably wide therapeutic index and can be systemically delivered with extrahepatic LNPs. Lead program shows high efficacy and safety in solid tumors resistant to other immuno-oncology agents. With roots at MIT, Harvard, Merck and BMS, Kernal’s management team has deep expertise in mRNA therapeutics with three FDA approvals and 120+ patents. Based in Cambridge, MA, the company is backed by Hummingbird, Amgen, HBM, Civilization Ventures, NASA, and Boeing.
Kestrel focuses on approaches to inhibition of mutated RAS protein in a variety of cancers. We use chemical screens, structural biophysical approaches, and medicinal chemistry to identify and characterize candidate inhibitors. We have four employees, have just been authorized to use our second tranche of funding, and are expanding.
Research Area:
Drug Discovery / Development
Small Molecules
Limax Biosciences is developing a strong and flexible hydrogel adhesive for wounds inside and outside the body
Coming Soon
Research Area:
Biological Product
Cell Therapy
Spun out of Harvard and MIT and backed by Versant Ventures, March Therapeutics ("March") is advancing molecular recording, genome mining and AI/ML to identify novel enzymatic activities from the tree of life and repurpose them for therapeutic applications.
Matrisome Bio is developing tools to deliver targeted therapies to the extracellular matrix (non-cellular components) of disease tissues such as tumors and fibrotic lesions in order to convert it from a barrier to a drug depot.
Research Area:
Platform Technology
Drug Delivery
NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Their innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors.
Novilla Pharmaceuticals is an early-stage biotech company developing two disruptive technologies developed by a former Harvard professor. Their programs utilize a precise delivery mechanism platform that uses charged ions to deliver medications through the intact dermal layer directly to nerves and other deeper tissues, which has not been possible before without the use of electrophoresis.
Research Area:
Platform Technology
Drug Delivery
Financed by Khosla Ventures, Pearl Bio brings together a broad patent portfolio from 15+ years of development in synthetic biology, genome editing, and ribosome engineering, converging in a new technology platform. Pearl's paradigm enables the biosynthesis of therapeutics and entirely new classes of biomaterials with novel genetically encoded chemistry incorporated with precision at multiple, distinct loci to produce precisely tailored biotherapeutics with tunable half-lives and reduced immunogenicity.
Research Area:
Platform Technology
R&D Tool
Coming Soon
Research Area:
Drug Discovery / Development
Small Molecules
Coming Soon
Research Area:
Drug Discovery / Development
Recombinant Therapeutic Protein
QurCan Therapeutics solves the problem of CNS and tissue-specific delivery of nucleotide and therapeutic molecules via its proprietary next generation nanoparticle platform, called "TERP". QurCan's team is committed to restoring health and transforming the lives of patients through the development of nanomedicine that requires the unique features of the TERP technology to address major unmet needs for the treatment of cancer and other major diseases.
Synolo is developing a suite of integrative technologies, leveraging unparalleled high-throughput sequencing, cell free protein synthesis and functional screening coupled with computational protein design and machine learning. Synolo's platform will power predictive diagnostics analytics, enhance novel target discovery as well as unlock novel therapeutic design spaces across multiple modalities.
For the human body to develop and function normally, the precise level of expression of each gene of the genome needs to be tightly regulated by epigenetics. When this balance is disrupted, alteration in gene expression can lead to severe genetic diseases for which no cure is available.
Regel’s technology utilizes a deactivated Cas system (dCas) which targets the epigenome without editing or damaging the DNA. This approach harnesses the natural mechanisms of gene regulation, allowing for efficient and permanent restoration of normal gene expression.
Research Area:
Biological Product
Gene Therapy
Coming Soon
Ribonaut Therapeutics is developing a novel small molecule platform capable of specifically degrading RNAs for the treatment of human diseases. Ribonaut's approach leverages the work of academic founder, Matthew Disney - Chair of the Department of Chemistry at Scripps Florida, and his foundational insights into the targeted recruitment of RNAses to specific RNA structural motifs using small molecules.
Research Area:
Drug Discovery / Development
Small Molecules
Rubik Therapeutics is developing programmed CAR-T/NK cell therapies for solid tumors. We have identified a set of highly selective, exclusive solid tumor targets as well as T cell modulators that will allow us to treat solid tumors while avoiding toxicity and immune evasion.
Research Area:
Biological Product
Cell Therapy
Skylark is pioneering gene therapies for patients with hearing loss.
Research Area:
Biological Product
Gene Therapy
Stipple Bio is unlocking cellular profiling and target discovery with epitope resolution.
Research Area:
Drug Discovery / Development
Recombinant Therapeutic Protein
Stratagen Bio is developing a novel class of sensors that provide quantitative and direct measurements of tissue oxygen, which are not possible with alternative sensors. Their sensor will enable more personalized and effective treatments for patients in a wide range of applications including oncology, wound healing, and tissue transplantation.
Research Area:
Medical Device
Diagnostic Device
Tevard Biosciences is a pioneering tRNA-based gene therapies to cure rare and severe genetic diseases with limited or no approved treatment options. Tevard was founded by MIT Professor and Whitehead Institute Founding Member Harvey Lodish, with life science entrepreneurs and executives Daniel Fischer and Warren Lammert, fathers of children with Dravet syndrome.
Transcera is transforming chronic disease treatment through a new approach to biologic medicines. Our novel lipid-based platform enables oral absorption and amplified distribution of large molecule therapeutics, so we can turn injections into pills and deliver biologics to hard-to-reach tissues such as the brain.
Research Area:
Biologic Medicine
Typewriter's technology will further expand current genome editing toolbox. More importantly, the technology possesses advantages over other existing editing methods and has potentials to address many unmet needs to cure diseases.
Research Area:
Cell & Gene Therapies
Viska.Bio Therapeutics induces Immunogenic Cell Death by treating cancer with a Fusion Protein between a tumor specific antibody and the enzyme Xanthine Oxidase. This produces superoxide in the tumor microenvironment oxidizing lipids which are incorporated into the lysosome which then becomes leaky releasing degradative enzymes which induce endopepsis - or cellular internal digestion. One result is that calreticulin, the eat me signal for DCs, migrates to the cell surface initiating the immunogenic feature. ODIN Therapeutics has produced a fusion protein to EGFR and shown that it produces the classic markers of Immunogenic Cell Death.
Research Area:
Drug Discovery / Development
Recombinant Therapeutic Protein
Vrata Therapeutics is developing a cell-penetrating antibody capable of delivering nucleic acid cargo directly to the cytoplasm of cells, especially in post-mitotic tissue such as skeletal muscle. This antibody allows avoidance of the endosomal escape problem, which severely limits the amount of nucleic acid therapeutic that actually gets to the site of action in the cell.
Zag Bio is developing therapeutics targeting the thymus to treat autoimmune diseases and patients with transplants. The thymus trains T cells to tell the difference between self and non-self and plays a critical role in the development of autoimmune disease. The company is developing therapeutics to train tissue-specific T regulatory cells to enable tolerance induction. There are currently no drugs that target the thymus.